Organon & Co. is a global healthcare company dedicated to advancing women's health and providing access to essential medicines and health solutions
Focused on a broad range of therapeutic areas, Organon develops and offers a variety of pharmaceuticals, including contraceptives and treatments for conditions affecting women through different life stages. The company aims to address health inequalities and improve patient outcomes by emphasizing innovation and collaboration in the healthcare landscape. With a commitment to empowering women and enhancing their well-being, Organon seeks to create a positive impact on global health.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQCORT) and its peers.
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys.
Shares of pharmaceutical company Organon (NYSEOGN)
jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations. While sales were flat year on year, strength in Established Brands helped offset declines in Biosimilars and Women's Health.
However, the company's full-year revenue outlook came in lower than expected, reflecting headwinds from foreign exchange and the loss of exclusivity for Atozet (the second-largest product) in key markets.
Overall, this quarter was decent, but not perfect.
Pharmaceutical company Organon (NYSEOGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s full-year revenue guidance of $6.23 billion at the midpoint came in 3.2% below analysts’ estimates. Its non-GAAP profit of $0.90 per share was 3.9% above analysts’ consensus estimates.
Organon (NYSEOGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2024 financial results on February 13, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
Organon (NYSEOGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT.
Organon (NYSEOGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older.1 Organon received the FDA approval prior to its extended target action date (PDUFA) of March 12, 2025.
Organon (NYSEOGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of December 12, 2024. The FDA has not raised any concerns regarding the safety and efficacy of VTAMA nor have they raised any concerns regarding the approvability of this indication.
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSEOGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA (denosumab).
Organon (NYSEOGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant NASDAQ: ROIVNASDAQROIV)
Organon (NYSEOGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSEOGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX11. The agreement licenses the global commercialization rights for the product, except for China, to Organon.
